News Articles
Latest articles, insights, and updates from the blog.
Contact Ketamine Resource
Send corrections, partnership questions, or advertising inquiries.
BPL-003 Shows Lasting Relief for Treatment-Resistant Depression
New phase 2a results for BPL-003 show sustained symptom reduction in treatment-resistant depression. What this means for ketamine patients.
A Chicago Fund Is Bridging Ketamine's Coverage Gap
A Chicago nonprofit is stepping in where insurers won't, covering ketamine treatment costs for patients with depression who can't afford to wait.
A Chicago Fund Is Closing Ketamine's Access Gap
A Chicago nonprofit is stepping in where insurers won't, funding ketamine treatment for depression patients who can't afford out-of-pocket costs.
Esketamine's Role in Treatment-Resistant Depression
Esketamine (Spravato) for treatment-resistant depression: how it works, who qualifies, REMS clinic visits, cost ranges, and Spravato vs IV ketamine.
Why Settling for 'Less Bad' Depression Isn't Enough
Clinicians are pushing for aggressive TRD care aimed at full remission. Here's what that means for patients exploring ketamine treatment options.
BXCL501 Enters Phase 2a Trial for Acute Stress & PTSD
A new DoD-backed Phase 2a trial is testing BXCL501 for acute stress reactions. Here's what it means for the evolving PTSD treatment landscape.
BPL-003 Shows Lasting TRD Relief in Phase 2a Results
New phase 2a data on BPL-003 shows sustained symptom reduction in treatment-resistant depression. Here's what it means for ketamine patients.
New Ketamine Nasal Spray Shows Lasting Depression Relief
BPL-003, a novel ketamine nasal spray for treatment-resistant depression, shows sustained symptom reduction in Phase 2a trials. What patients should know.
Ketamine Compounding Regulations in 2026: What Has Changed
An overview of the latest regulatory developments affecting compounded ketamine in 2026, including FDA enforcement updates, state-level changes, and the impact on patient access.
Ketamine Clinic Safety Standards: What Patients Should Expect
An overview of emerging safety standards for ketamine treatment clinics, including clinical protocols, monitoring requirements, provider qualifications, and what patients should look for when evaluating a ketamine provider.
DEA Telehealth Prescribing Rules: What Changed in 2025
DEA telehealth prescribing rules for controlled substances in 2025: Ryan Haight extensions, in-person visit triggers, and what they mean for ketamine access.
Compounding Pharmacies and Ketamine: What Patients Should Know
What patients should know about compounding pharmacies that prepare ketamine formulations, including quality standards, regulatory oversight, and how to choose a pharmacy.